355 related articles for article (PubMed ID: 26296890)
1. Amyloid Precursor Protein (APP) Metabolites APP Intracellular Fragment (AICD), Aβ42, and Tau in Nuclear Roles.
Multhaup G; Huber O; Buée L; Galas MC
J Biol Chem; 2015 Sep; 290(39):23515-22. PubMed ID: 26296890
[TBL] [Abstract][Full Text] [Related]
2. Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease.
Kirouac L; Rajic AJ; Cribbs DH; Padmanabhan J
eNeuro; 2017; 4(2):. PubMed ID: 28374012
[TBL] [Abstract][Full Text] [Related]
3. Tau Protein Mediates APP Intracellular Domain (AICD)-Induced Alzheimer's-Like Pathological Features in Mice.
Ghosal K; Fan Q; Dawson HN; Pimplikar SW
PLoS One; 2016; 11(7):e0159435. PubMed ID: 27459671
[TBL] [Abstract][Full Text] [Related]
4. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the COPI coatomer subunit α-COP induce release of Aβ-42 and amyloid precursor protein intracellular domain and increase tau oligomerization and release.
Astroski JW; Akporyoe LK; Androphy EJ; Custer SK
Neurobiol Aging; 2021 May; 101():57-69. PubMed ID: 33582567
[TBL] [Abstract][Full Text] [Related]
6. Small things matter: Implications of APP intracellular domain AICD nuclear signaling in the progression and pathogenesis of Alzheimer's disease.
Bukhari H; Glotzbach A; Kolbe K; Leonhardt G; Loosse C; Müller T
Prog Neurobiol; 2017 Sep; 156():189-213. PubMed ID: 28587768
[TBL] [Abstract][Full Text] [Related]
7. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
8. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
[TBL] [Abstract][Full Text] [Related]
9. Looking at Alzheimer's Disease Pathogenesis from the Nuclear Side.
D'Andrea L; Stringhi R; Di Luca M; Marcello E
Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572474
[TBL] [Abstract][Full Text] [Related]
10. BACE1 RNA interference improves spatial memory and attenuates Aβ burden in a streptozotocin-induced tau hyperphosphorylated rat model.
Yu CJ; Liu W; Chen HY; Wang L; Zhang ZR
Cell Biochem Funct; 2014 Oct; 32(7):590-6. PubMed ID: 25230339
[TBL] [Abstract][Full Text] [Related]
11. Alphabeta hinders nuclear targeting of AICD and Fe65 in primary neuronal cultures.
Henriques AG; Vieira SI; da Cruz e Silva EF; da Cruz e Silva OA
J Mol Neurosci; 2009 Sep; 39(1-2):248-55. PubMed ID: 19340611
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
13. APP metabolism regulates tau proteostasis in human cerebral cortex neurons.
Moore S; Evans LD; Andersson T; Portelius E; Smith J; Dias TB; Saurat N; McGlade A; Kirwan P; Blennow K; Hardy J; Zetterberg H; Livesey FJ
Cell Rep; 2015 May; 11(5):689-96. PubMed ID: 25921538
[TBL] [Abstract][Full Text] [Related]
14. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
15. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
[TBL] [Abstract][Full Text] [Related]
16. Melatonin Induction of APP Intracellular Domain 50 SUMOylation Alleviates AD through Enhanced Transcriptional Activation and Aβ Degradation.
Liu YC; Hsu WL; Ma YL; Lee EHY
Mol Ther; 2021 Jan; 29(1):376-395. PubMed ID: 32950104
[TBL] [Abstract][Full Text] [Related]
17. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
[TBL] [Abstract][Full Text] [Related]
18. The blockage of the Nogo/NgR signal pathway in microglia alleviates the formation of Aβ plaques and tau phosphorylation in APP/PS1 transgenic mice.
Fang Y; Yao L; Li C; Wang J; Wang J; Chen S; Zhou XF; Liao H
J Neuroinflammation; 2016 Mar; 13(1):56. PubMed ID: 26939570
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological targeting of the β-amyloid precursor protein intracellular domain.
Branca C; Sarnico I; Ruotolo R; Lanzillotta A; Viscomi AR; Benarese M; Porrini V; Lorenzini L; Calzà L; Imbimbo BP; Ottonello S; Pizzi M
Sci Rep; 2014 Apr; 4():4618. PubMed ID: 24714650
[TBL] [Abstract][Full Text] [Related]
20. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
